profit from every $100 of sales.
$0$100
Octave Specialty Group
$5.09-3.78% today
-48.6% in 1 year
1-year low $3.941-year high $9.91
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
Not measured for banks and insurers: deposits and policy reserves count as debt, so the usual debt test says nothing about them.
Money in, money out
What Octave Specialty Group sold, what it kept, and what it did with the cash.
Sales went from $53.6 million in 2022 to $249 million in 2025, with -$262 million of profit last year.
SalesProfit
Octave Specialty Group vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Octave Specialty Group | No profit yet | ||
 Assurant | 18.1× · Fair price | ||
 Fidelity National Financial | 19.2× · Fair price | ||
 Beazley | 8.5× · Cheap | ||
 Medibank Private | 30.1× · Expensive |
AI analysis
An AI analyst reads Octave Specialty Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 54 | 125 | 235 | 249 | |
| – | – | – | – | |
| – | – | – | – | |
| -32 | -19 | -31 | -40 | |
| 521 | 4 | -556 | -262 | |
| 11.31 | 0.18 | -11.96 | -5.93 | |
| – | – | – | – | |
| – | – | – | – | |
| 972.3% | 2.9% | -236.5% | -105.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 7,973 | 8,428 | 8,058 | 2,223 |
| Cash | 14 | 19 | 47 | 68 |
| Total debt | 3,746 | 0 | 150 | 118 |
| Total liabilities | 6,648 | 6,997 | 6,863 | 1,137 |
| 1,252 | 1,362 | 798 | 716 | |
| 46 | 46 | 47 | 47 | |
| -0.6% | -1.4% | -4.2% | -7.8% | |
| 41.6% | 0.3% | -69.7% | -36.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 70 | 37 | 1 | -52 | |
| – | – | – | – | |
| 70 | 37 | 1 | -52 | |
| Dividends paid | – | – | – | – |
| 14 | 5 | 12 | 30 | |
| 11 | 12 | – | – |
This is a bank or insurer, so cash-flow and debt ratios are left out: borrowing and lending is the business itself. Price to book and return on equity are the measures that matter here.
Valuation
- –
- 18.3×
- –
- 0.4×
- 0.9×
- -114.1%
- 0.0%
Profitability
- -105.2%
- -6.4%
- -14.8%
- -25.5%
- -8.8%
Growth
- +66.8%
- –
- –
- +0.3%
How it ranks in Financial Services
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 827
Bottom 4%of 709
Top 5%of 879
Bottom 6%of 926
What analysts expect
- Average price target
- $14.00
- Range
- $10.00 – $18.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.37 | 0.02 | +1,750.0% |
| Feb 23, 2026 | -0.02 | -0.21 | +90.5% |
| Nov 10, 2025 | -0.21 | -0.23 | +8.7% |
| Aug 7, 2025 | -0.22 | -0.24 | +8.3% |
| May 12, 2025 | -0.13 | -0.07 | −85.7% |
| Feb 26, 2025 | -0.12 | 0.06 | −300.0% |
| Nov 12, 2024 | -0.46 | 0.08 | −675.0% |
| Aug 5, 2024 | 0.18 | 0.19 | −5.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
62Pass
Philip Fisher
46No pass
Peter Lynch
70Pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
23No pass
Questions about Octave Specialty Group
Is Octave Specialty Group a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Octave Specialty Group AI analysis
What does Octave Specialty Group do?
Octave Specialty Group, Inc. operates as a financial services holding company. It operates in two segments, Specialty Property and Casualty Insurance; and Insurance Distribution. It is in Insurance - Specialty.
Does Octave Specialty Group pay a dividend?
No. Octave Specialty Group does not pay a dividend at the moment; in 2025 it returned $29.9 million to shareholders by buying back its own shares.
Is Octave Specialty Group stock halal?
No. Octave Specialty Group does not pass our halal screen: its main business, conventional insurance, is not permitted. How we check
How has Octave Specialty Group stock done over the past year?
Down 48.6% over the past twelve months, to $5.09. It traded between $3.94 and $9.91 and is 48.6% below its high.
Who are Octave Specialty Group's competitors?
The largest listed companies in the same industry are Assurant, Fidelity National Financial, Beazley and Medibank Private. The peers table on this page compares their profit, growth and price with Octave Specialty Group's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.